AFP and hepatocellular carcinoma: In a very recent study from Europe, it has been clearly reported that “use of changes in serum levels of biomarkers for assessment of response (i.e., AFP levels) is under investigation” [4]; similarly, the US national conference for liver allocation in HCC patients has established that “allocation points will be based on a candidate's calculated MELD score plus the following factors.